Search Results

Acasti Pharma Inc. announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

Acasti Pharma Inc. today announced financial results and business highlights for the year ended March 31, 2024.

Acasti Pharma Inc. announced that the Company’s pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended December 31, 2023.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company) today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7-9, 2024 in Phoenix, AZ.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST) today announced financial and operational results for the fiscal year ended March 31, 2023.

Acasti Pharma Inc. today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.

Acasti Pharma Inc. today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended September 30, 2023.